Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II adjuvant-dose selection study of recombinant gE herpes zoster vaccine in adults aged 50 years and older
2008-005120-86Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2008
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Zoster vaccine recombinant in herpes zoster (HZ) (4 arms), sponsored by GSK. Primary endpoint: gE- and VZV-specific CD4 T-cell response at Month 3. Started Oct 2008; status: completed.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on 2008-005120-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005120-86.